Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Best Buy Co IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs Charles River Laboratories Intl. Inc — how do they compare? Best Buy Co Inc trades at $83.6 (market cap $17.55B), while Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B). The key difference: Best Buy Co Inc is the larger of the two by market cap, and Best Buy Co Inc pays a 4.61% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

BBYCRL
Market Cap
$17.55B$13.46B
Sector
Consumer CyclicalHealth
52-Week High
$90.17$282.00
52-Week Low
$55.52$145.57
Enterprise Value
$19.93B$16.30B
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

Best Buy (BBY) trades at $82.99, up 0.68% on the day, with a neutral technical outlook despite bullish moving averages. The company shows strong profitability with 39.1% ROE and 7.88% ROA, though revenue has declined from $51.8B in 2022 to $41.5B in 2025. Recent leadership changes include a new CFO appointment and marketing chief departure, while the company tests smaller store formats to drive growth.

The stock offers modest upside to the $84.31 consensus target with solid fundamentals but faces revenue pressure and leadership transition risks. Positive cash flow trends and consistent earnings beats support the investment case, though competitive retail pressures and macroeconomic headwinds remain concerns.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Returns comparison

Trailing returns across standard periods

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL